Eli Lilly and Co (LLY) announced on Monday, that the US Food and Drug Administration (FDA) had given tentative approval to its diabetes insulin drug called Basaglar. The development of this drug, which is administered intraveneously and aims to control blood sugar levels in diabetic patients, is a joint effort by Eli Lilly and Boehringer Ingelheim Corporation.
On Friday, the US Food & Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Co.’s (LLY) drug Jardiance (empagliflozin) as an add-on to diet and exercise to improve glycemic control (blood sugar levels) in adults with type 2 diabetes (T2D). The approval comes after the FDA had earlier rejected empagliflozin because of manufacturing deficiencies at Boehringer’s facility, where the drug is manufactured.
Sanofi SA ADR (SNY) announced today that the French-based pharmaceutical giant has entered into a licensing agreement with Mannkind Corporation (MNKD) for the manufacture and marketing of the insulin inhaler Afrezza.
The announcement comes after the Food and Drug Administration (FDA) approved Afrezza for marketing on June 27. Sanofi and Mannkind plan to launch the drug in the US in early 2015.
By Bill Berkrot(Reuters) - An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study.The Lilly drug, dulaglutide, achieved the primary goal of the 599-patient study by demonstrating so-called non-inferiority to the highest approved dose of Victoza after 26 weeks, according to initial results released by the company on Tuesday.
People with insulin resistance and type 2 diabetes are at higher risk of developing plaques associated with Alzheimer's, Japanese researchers said in a study out Wednesday.The research, published in the American Academy of Neurology, involved 135 people with an average age of 67 from Hisayama, Japan.The group was tested for blood sugar levels and followed over a period of 10-15 years to detect signs of Alzheimer's.
Sanofi SA (ADR) (SNY) beat the Street’s earnings expectations for the second quarter of its fiscal year ‘14 (2QFY14, ended June 30); the company then raised its full-year guidance. The French drug maker generated revenue of $10.8 billion (€8.08 billion) for the quarter, up 0.9% year-over-year (YoY). The increase in sales incorporates exchange rate movements; disregarding the same, revenue was up 6.4% YoY.
ByGlen S. Woods:Diabetes, a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces, affects 347 million people worldwide.